An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is intended to evaluate the safety, tolerability, and possible effectiveness of an
investigational humanized monoclonal antibody (CAL) to the parathyroid hormone-related
protein (PTHrP) when compared to zoledronic acid in patients with breast cancer metastatic to
bone.
The study will also evaluate the possible effects of both study drugs on performance status,
markers of bone metabolism, and skeletal events related to bone metastasis including elevated
blood calcium levels, bone pain, metastatic lesions, complications and interventions. The
levels of CAL in the blood will also be evaluated.